1150586-64-3Relevant articles and documents
New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo
Brizzi, Antonella,Brizzi, Vittorio,Cascio, Maria Grazia,Corelli, Federico,Guida, Francesca,Ligresti, Alessia,Maione, Sabatino,Martinelli, Adriano,Pasquini, Serena,Tuccinardi, Tiziano,Di Marzo, Vincenzo
experimental part, p. 2506 - 2514 (2010/03/26)
Bearing in mind the pharmacophoric requirements of both (-)-trans-Δ9-tetrahydrocannabinol (THC) and anandamide (AEA), we designed a novel pharmacophore consisting of both a rigid aromatic backbone and a flexible chain with the aim to develop a series of stable and potent ligands of cannabinoid receptors. In this paper we report the synthesis, docking studies, and structure-activity relationships of new resorcinol-anandamide "hybrids" differing in the side chain group. Compounds bearing a 2-methyloctan-2-yl group at position 5 showed a significantly higher affinity for cannabinoid (CB) receptors, in particular when an alkyloxy chain of 7 or 10 carbon atoms was also present at position 1. Derivative 32 was a potent CB 1 and CB2 ligand, with Ki values similar to that of WIN 55-212 and potent antinociceptive activity in vivo. Moreover, derivative 38, although less potent, proved to be the most selective ligand for CB2 receptor (Ki(CB1)) 1 μM, K i(CB2)) 35 nM).